Neuronix

Company Overview

Snapshot

Founded in January 2008 by Jonathan Bentwich, Neuronix operated with 11–50 employees. The company secured $17.5 million across three funding rounds. Neuronix ceased operations in April 2020.

Business overview

Neuronix is a Health Tech & Life Sciences company focused on developing methods to modify the treatment course for Alzheimer's disease. Its core technology, the neuroAD system, utilizes noninvasive cortical enhancement through magnetic stimulation interlaced with cognitive training, targeting specific brain regions affected by Alzheimer's. The company's patented technology aims to induce long-term potentiation associated with learning and memory processes. Neuronix's product, neuroAD, is CE marked for the treatment of mild to moderate Alzheimer's disease and serves the healthcare market, particularly providers, with a focus on neurology and medical devices.

Strategic signal

In March 2019, an FDA Advisory Panel rejected Neuronix's neuroAD system for Alzheimer's Disease. This event signaled a significant regulatory hurdle for the company's expansion into the US market, impacting its commercial trajectory and investor confidence.

Company Intelligence Q&A

What is Neuronix's primary focus?

Neuronix develops methods for modifying the course of treatment for Alzheimer's disease, utilizing magnetic stimulation technology combined with cognitive training.

When was Neuronix founded?

Neuronix was founded in January 2008.

What is the status of Neuronix?

Neuronix is currently non-active and ceased to operate in April 2020.

What was a significant regulatory challenge for Neuronix?

In March 2019, an FDA Advisory Panel rejected Neuronix's neuroAD system for Alzheimer's Disease, posing a significant challenge to its market entry in the United States.

What was a key product development for Neuronix?

Neuronix developed the neuroAD system, a noninvasive cortical enhancer technology that is CE marked for the treatment of mild to moderate Alzheimer's disease in Europe.